Immix Biopharma, Inc.IMMXNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank59
3Y CAGR+2.0%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+2.0%/yr
Quarterly compound
Percentile
P59
Within normal range
vs 3Y Ago
1.1x
Modest growth
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 15.40% |
| Q2 2025 | 101.13% |
| Q1 2025 | 43.71% |
| Q4 2024 | -69.08% |
| Q3 2024 | 99.88% |
| Q2 2024 | -31.54% |
| Q1 2024 | 4.77% |
| Q4 2023 | 47.23% |
| Q3 2023 | -4.67% |
| Q2 2023 | 67.49% |
| Q1 2023 | -41.70% |
| Q4 2022 | 225.11% |
| Q3 2022 | 14.51% |
| Q2 2022 | -3.46% |
| Q1 2022 | 6716.06% |
| Q4 2021 | -68.89% |
| Q3 2021 | -52.69% |
| Q2 2021 | 152.66% |
| Q1 2021 | -70.19% |
| Q4 2020 | 85.36% |
| Q3 2020 | -24.99% |
| Q2 2020 | -0.00% |
| Q1 2020 | 0.00% |